Literature DB >> 18203260

Phosphoproteomic analysis of Leishmania donovani pro- and amastigote stages.

Miguel A Morales1, Reiko Watanabe, Christine Laurent, Pascal Lenormand, Jean-Claude Rousselle, Abdelkader Namane, Gerald F Späth.   

Abstract

Following transmission to the vertebrate host, the protozoan parasite Leishmania donovani differentiates into the pathogenic amastigote stage that is adapted for intracellular survival. This developmental transition is induced by environmental factors including elevated temperature and acidic pH and is likely transduced by signaling cascades involving protein kinases and their downstream phosphoprotein substrates. These signaling networks are highly adapted to the specific nutritional and physiological requirements of the organism and thus studying Leishmania phosphorylation may allow important insight into the parasite-specific biology. We used a gel-based approach to investigate qualitative and quantitative changes of the phosphoproteome of the major L. donovani life cycle stages. Phosphoproteins were purified by immobilized metal affinity chromatography (IMAC), separated by IEF and SDS-PAGE using pH 4-7 IPG immobiline strips, revealed by fluorescent multiplex staining, and identified by MALDI-MS and MS/MS. Our analysis allowed us to establish a first repertoire of the Leishmania phosphoproteome and to identify phosphoproteins implicated in stress- and heat shock response, RNA/protein turnover, metabolism, and signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18203260     DOI: 10.1002/pmic.200700697

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  30 in total

1.  Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Eugenio Barone; Marzia Perluigi; Chiara Cini; Cesare Mancuso; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-04-13       Impact factor: 4.044

2.  From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.

Authors:  Emilie Durieu; Eric Prina; Olivier Leclercq; Nassima Oumata; Nicolas Gaboriaud-Kolar; Konstantina Vougogiannopoulou; Nathalie Aulner; Audrey Defontaine; Joo Hwan No; Sandrine Ruchaud; Alexios-Leandros Skaltsounis; Hervé Galons; Gerald F Späth; Laurent Meijer; Najma Rachidi
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Phosphoproteome dynamics reveal heat-shock protein complexes specific to the Leishmania donovani infectious stage.

Authors:  Miguel A Morales; Reiko Watanabe; Mariko Dacher; Philippe Chafey; José Osorio y Fortéa; David A Scott; Stephen M Beverley; Gabi Ommen; Joachim Clos; Sonia Hem; Pascal Lenormand; Jean-Claude Rousselle; Abdelkader Namane; Gerald F Späth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

4.  The co-chaperone SGT of Leishmania donovani is essential for the parasite's viability.

Authors:  Gabi Ommen; Mareike Chrobak; Joachim Clos
Journal:  Cell Stress Chaperones       Date:  2009-12-02       Impact factor: 3.667

5.  Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability.

Authors:  Wai-Lok Yau; Thierry Blisnick; Jean-François Taly; Manuela Helmer-Citterich; Cordelia Schiene-Fischer; Olivier Leclercq; Jing Li; Dirk Schmidt-Arras; Miguel A Morales; Cedric Notredame; Daniel Romo; Philippe Bastin; Gerald F Späth
Journal:  PLoS Negl Trop Dis       Date:  2010-06-29

6.  Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.

Authors:  Najma Rachidi; Jean François Taly; Emilie Durieu; Olivier Leclercq; Nathalie Aulner; Eric Prina; Pascale Pescher; Cedric Notredame; Laurent Meijer; Gerald F Späth
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

7.  Phosphoproteomic analysis of the human pathogen Trypanosoma cruzi at the epimastigote stage.

Authors:  Ernesto S Nakayasu; Matthew R Gaynor; Tiago J P Sobreira; Jeremy A Ross; Igor C Almeida
Journal:  Proteomics       Date:  2009-07       Impact factor: 3.984

8.  Regulation dynamics of Leishmania differentiation: deconvoluting signals and identifying phosphorylation trends.

Authors:  Polina Tsigankov; Pier Federico Gherardini; Manuela Helmer-Citterich; Gerald F Späth; Peter J Myler; Dan Zilberstein
Journal:  Mol Cell Proteomics       Date:  2014-04-16       Impact factor: 5.911

9.  RNA editing and mitochondrial activity in promastigotes and amastigotes of Leishmania donovani.

Authors:  Martina Nebohácová; Christine E Kim; Larry Simpson; Dmitri A Maslov
Journal:  Int J Parasitol       Date:  2008-12-10       Impact factor: 3.981

10.  Leishmania major MPK7 protein kinase activity inhibits intracellular growth of the pathogenic amastigote stage.

Authors:  Miguel A Morales; Pascale Pescher; Gerald F Späth
Journal:  Eukaryot Cell       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.